P/1259-637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Fernand LABRIE

Serial No.: 10/052,803

Filed: November 7, 2001

Date: June 22, 2007

Confirmation No.: 3989

Group Art Unit: 1617

Examiner: Yong Soo Chong

For: **SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT/SUBMISSION

Sir:

This is a response to the most recent Office Action in the above-identified application. Reconsideration of the application is respectfully requested.

FEE CALCULATION

✔ No additional fee is required.

	NO. CLAIMS AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		EXTRA PRESENT		RATE	ADDIT. FEE
TOTAL	20	MINUS	43	* =	0	X	($25 SE or $50)	$0
INDEP.	2	MINUS	4	** =	0	X	($100 SE or $200)	$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						X	($180 SE or $360)	$
							TOTAL	$0

* not less than 20 ** not less than 3

In the event the actual fee is greater than the payment submitted or is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

CONTINGENT EXTENSION REQUEST

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. § 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 C.F.R. § 1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

SUMMARY OF AMENDMENTS

1. ___ If checked, an abstract (an amended abstract) is submitted herewith.

2. ___ If checked, amendment(s) to the drawings are submitted herewith.

3. ___ If checked, amendment(s) to the specification are submitted herewith.

4. ✔ If checked, amendment(s) to the claims are submitted herewith.

wherein Z is either absent or selected from the group consisting of $-CH_2-$,-0-,-S- and $-NR_3-$ (R_3 being hydrogen or lower alkyl);

wherein the R100 is a bivalent moiety which distances L from the ring carbon to which R_{100} is attached by 4-10 intervening atoms;

wherein L is a bivalent or trivalent moiety selected from the group of -SO-, -CON-, -N<, and -SON<;

wherein G_1 is selected from the group consisting of hydrogen, a C_1 to C_5 hydrocarbon, and a bivalent moiety which in combination with G_2 and L is a 5-to 7- membered heterocyclic ring, wherein the foregoing may optionally be halogenated or unsaturated;

wherein G_2 is either absent or selected from the group consisting of hydrogen, a C_1 to C_5 hydrocarbon, and a bivalent moiety which in combination with G_1 and L is a 5-to 7- membered heterocyclic ring, wherein the foregoing may optionally be halogenated or unsaturated;

wherein G_3 is selected from the group consisting of hydrogen, methyl and ethyl;

wherein said composition is a pharmaceutical dosage form suitable for administering to a patient.

Claim 2 (Previously presented) The pharmaceutical composition of claim 1, further comprising:

a therapeutically effective amount of at least one additional agent selected from the group consisting of bisphosphonate, progestogen, an androgenic agent, testosterone, dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3β,17β-diol, 4-androstene-3,17-dione, and a prodrug of any of the foregoing additional agents.

Claims 3-12 (Canceled)

Claim 13 (Previously presented) The pharmaceutical composition of claim 1, wherein the compound is a benzopyran of the following general structure: